VERKAZIA is a prescription medication primarily used in the treatment of vernal keratoconjunctivitis (VKC), a rare and recurrent allergic eye condition. VKC is characterized by inflammation of the surface of the eye, leading to severe discomfort, itching, light sensitivity, and vision impairment. VERKAZIA contains the active ingredient cyclosporine, which is an immunomodulating agent. It works by suppressing the immune system's response that causes the inflammation in the eyes, thereby providing relief from the symptoms associated with VKC. VERKAZIA is administered as eye drops and is designed for use in patients who have not adequately responded to conventional treatments. Its use must be under the guidance and prescription of a healthcare professional, ensuring its appropriateness and monitoring for any potential side effects.